FY22 Pancreatic Cancer Research Program (PCARP)

PROGRAM DESCRIPTION

The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. The goal of the PCARP is to reduce the burden of pancreatic cancer among Service Members, Veterans, their families, and the American public. The mission of the PCARP is to promote rigorous, innovative, high-impact research that leads to earlier pancreatic cancer diagnosis and new therapeutic tools through collaboration. Preproposal is required; application submission is by invitation only. Please refer to the links in the sidebar for more information about each award mechanism and application (pre-proposal) instructions. 

Idea Development Award (IDA)

Established Single PI Option: $500K / 3 years

Early Career Investigator Partnering PI Option: $650K / 3 years

The PCARP Idea Development Award supports the development of innovative, high-risk/high reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.

Translational Research Partnership Award (TRPA)

Funding Details: $750K / 3 years 

The FY22 PCARP Translational Research Partnership Award supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in pancreatic cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must function as a research scientist and the other partner as a clinician investigator. It should be clear that both have had equal intellectual input in the design of the research project. Projects involving convergence science partnerships are strongly encouraged. At least one partner must have expertise either in pancreatic cancer research or pancreatic cancer patient care. Inclusion of experts from outside the pancreatic cancer field is encouraged. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism. Full support for large-scale clinical trials is not expected; retrospective tissue analysis, correlative studies, or small pilot clinical trials are permitted.